Radiotherapy & Oncology
Volume 97, Issue 2 , Pages 270-275 , November 2010

Comparison of patient-reported late treatment toxicity (LENT–SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy

  • Kean Fatt Ho

      Affiliations

    • Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
    • Corresponding Author InformationCorresponding author. Address: Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
    • ,
  • Damien J.J. Farnell

      Affiliations

    • Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • Jacqueline A. Routledge

      Affiliations

    • Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • Meriel P. Burns

      Affiliations

    • Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • Andrew J. Sykes

      Affiliations

    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • Nick J. Slevin

      Affiliations

    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • Susan E. Davidson

      Affiliations

    • Academic Radiation Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
    • Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Received 28 April 2009 ,Revised 9 December 2009 ,Accepted 29 January 2010.

References 

  1. Williams MV. The cancer reform strategy. Clin Oncol (R Coll Radiol). 2008;20:271–274
  2. Evans S, Tritter J, Barley V, Daykin N, McNeill J, Palmer N, et al. User involvement in UK cancer services: bridging the policy gap. Eur J Cancer Care (Engl). 2003;12:331–338
  3. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19–22
  4. Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol. 2006;78:298–305
  5. Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, et al. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys. 2008;70:330–337
  6. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  7. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–3589
  8. Burlage FR, Roesink JM, Kampinga HH, Coppes RP, Terhaard C, Langendijk JA, et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys. 2008;70:14–22
  9. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121–5127
  10. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:445–453
  11. Bruner DW. Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials?. J Clin Oncol. 2007;25:5345–5347
  12. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903–909
  13. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923–931
  14. LENT SOMA tables . Radiother Oncol. 1995;35:17–60
  15. LENT SOMA scales for all anatomic sites . Int J Radiat Oncol Biol Phys. 1995;31:1049–1091
  16. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003;55:93–98
  17. Davidson SE, Trotti A, Ataman OU, Seong J, Lau FN, da Motta NW, et al. Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys. 2007;69:1218–1221
  18. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17:1008–1019
  19. Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 30) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000;36:1796–1807
  20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  21. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–3776
  22. Ho K, Farnell D, Routledge J, Burns M, Sykes A, Slevin N, et al. Developing a CTCAE patient questionnaire for late toxicity after head and neck radiotherapy. Eur J Cancer. 2009;45:1992–1998
  23. Routledge JA, Burns MP, Swindell R, Khoo VS, West CM, Davidson SE. Evaluation of the LENT–SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:502–510
  24. EORTC TEOfRaToC. EORTC QLQ-C30 scoring manual; 2001.
  25. Davidson SE, Burns MP, Routledge JA, Swindell R, Bentzen SM, West CM. Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiother Oncol. 2003;69:195–200
  26. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol. 2003;13:189–202
  27. Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. Radiother Oncol. 2003;68:105–111
  28. Snyers A, Janssens GO, Twickler MB, Hermus AR, Takes RP, Kappelle AC, et al. Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int J Radiat Oncol Biol Phys. 2008;
  29. Wenz F, Welzel G, Keller A, Blank E, Vorodi F, Herskind C, et al. Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer. Breast. 2008;17:617–622

PII: S0167-8140(10)00069-1

doi: 10.1016/j.radonc.2010.01.017

Radiotherapy & Oncology
Volume 97, Issue 2 , Pages 270-275 , November 2010

Article Tools

* Image Usage & Resolution